“…The decrease in the stented length of the aorta reduces the cardiovascular hemodynamic consequences. 9,11 The retrospective single-center report of 23 cases presented by Costache et al 1 addresses the use of the MFM device in AD and adds to the existing data available, providing further information for physicians who need to be aware of MFM performance. However, no matter how informative this low-volume case series is, there is no escaping the controversy surrounding flow modulation technology in aortic pathology.…”